NEFL Antibody - #DF6060

(1)   (4)  
Product: NEFL Antibody
Catalog: DF6060
Description: Rabbit polyclonal antibody to NEFL
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Chicken
Mol.Wt.: 62kDa; 62kD(Calculated).
Uniprot: P07196
RRID: AB_2838029

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Chicken(100%)
Clonality:
Polyclonal
Specificity:
NEFL Antibody detects endogenous levels of total NEFL.
RRID:
AB_2838029
Cite Format: Affinity Biosciences Cat# DF6060, RRID:AB_2838029.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

150kDa medium; 160 kDa neurofilament protein; 2 kDa neurofilament protein; 200 kDa neurofilament protein; 68 kDa neurofilament protein; AI847934; CMT1F; CMT2CC; CMT2E; FLJ53642; KIAA0845; light molecular weight neurofilament protein; Micro glutamic acid-rich protein; mKIAA0845; Nef3; NEFH; NEFL; NEFM; Neurofilament 3; Neurofilament heavy polypeptide 200kDa; Neurofilament heavy polypeptide; Neurofilament light polypeptide 68kDa; Neurofilament light polypeptide; Neurofilament medium polypeptide 150kDa; Neurofilament medium polypeptide; Neurofilament protein heavy polypeptide; Neurofilament protein light chain; Neurofilament protein light polypeptide; Neurofilament protein medium polypeptide; neurofilament subunit NF-L; Neurofilament triplet H protein; Neurofilament triplet L protein; Neurofilament triplet M protein; neurofilament-3 (150 kD medium); NF-H; NF-L; NF-M; NF160; NF165; NF200; NF68; NFH; NFL; NFM; NFM_HUMAN; PPP1R110; protein phosphatase 1, regulatory subunit 110;

Immunogens

Immunogen:
Uniprot:

P07196(NFL_HUMAN) >>Visit HPA database.

Gene(ID):
NEFL(4747)
Description:
The cytoskeleton consists of three types of cytosolic fibers: actin microfilaments, intermediate filaments, and microtubules. Neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM), and heavy (NFH) subunits (1). Similar in structure to other intermediate filament proteins, neurofilaments have a globular amino-terminal head, a central α-helical rod domain, and a carboxy-terminal tail. A heterotetrameric unit (NFL-NFM and NFL-NFH) forms a protofilament, with eight protofilaments comprising the typical 10 nm intermediate filament (2). While neurofilaments are critical for radial axon growth and determine axon caliber, microtubules are involved in axon elongation. PKA phosphorylates the head domain of NFL and NFM to inhibit neurofilament assembly (3,4). Neurofilament accumulations are found in many human neurological disorders including Parkinson's disease (in Lewy bodies along with α-synuclein), Alzheimer's disease, Charcot-Marie-Tooth disease, and Amyotrophic Lateral Sclerosis (ALS) (1).
Sequence:
MSSFSYEPYYSTSYKRRYVETPRVHISSVRSGYSTARSAYSSYSAPVSSSLSVRRSYSSSSGSLMPSLENLDLSQVAAISNDLKSIRTQEKAQLQDLNDRFASFIERVHELEQQNKVLEAELLVLRQKHSEPSRFRALYEQEIRDLRLAAEDATNEKQALQGEREGLEETLRNLQARYEEEVLSREDAEGRLMEARKGADEAALARAELEKRIDSLMDEISFLKKVHEEEIAELQAQIQYAQISVEMDVTKPDLSAALKDIRAQYEKLAAKNMQNAEEWFKSRFTVLTESAAKNTDAVRAAKDEVSESRRLLKAKTLEIEACRGMNEALEKQLQELEDKQNADISAMQDTINKLENELRTTKSEMARYLKEYQDLLNVKMALDIEIAAYRKLLEGEETRLSFTSVGSITSGYSQSSQVFGRSAYGGLQTSSYLMSTRSFPSYYTSHVQEEQIEVEETIEAAKAEEAKDEPPSEGEAEEEEKDKEEAEEEEAAEEEEAAKEESEEAKEEEEGGEGEEGEETKEAEEEEKKVEGAGEEQAAKKKD

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Chicken
100
Pig
0
Horse
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P07196 As Substrate

Site PTM Type Enzyme
S2 Acetylation
S3 Phosphorylation
Y14 Phosphorylation
K15 Ubiquitination
T21 Phosphorylation Q00535 (CDK5) , P28482 (MAPK1)
R23 Methylation
R30 Methylation
R37 Methylation
S56 Phosphorylation
S103 Phosphorylation
T154 Phosphorylation
K157 Ubiquitination
S215 Phosphorylation
S221 Phosphorylation
K271 Ubiquitination
K362 Acetylation
K370 Ubiquitination
Y372 Phosphorylation
K379 Acetylation
Y389 Phosphorylation
S472 Phosphorylation
T520 Phosphorylation

Research Backgrounds

Function:

Neurofilaments usually contain three intermediate filament proteins: L, M, and H which are involved in the maintenance of neuronal caliber.

PTMs:

O-glycosylated.

Phosphorylated in the head and rod regions by the PKC kinase PKN1, leading to the inhibition of polymerization.

Ubiquitinated in the presence of TRIM2 and UBE2D1.

Subunit Structure:

Interacts with ARHGEF28. Interacts with TRIM2.

Family&Domains:

The extra mass and high charge density that distinguish the neurofilament proteins from all other intermediate filament proteins are due to the tailpiece extensions. This region may form a charged scaffolding structure suitable for interaction with other neuronal components or ions.

Belongs to the intermediate filament family.

Research Fields

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

References

1). Exosomes derived from human induced pluripotent stem cell-derived neural progenitor cells protect neuronal function under ischemic conditions. Neural Regeneration Research (PubMed: 33642395) [IF=6.1]

Application: WB    Species: Human    Sample: neural progenitor cells;

Figure 3 Effect of iPSC-NPC-derived exosomes (OGD+iNPC-exo) on expression of the PTEN/AKT signaling pathway and of synaptic plasticity-related proteins in OGD induced neurons. (A–C) mRNA expression (A) and protein expression (B, C) of the PTEN/AKT signaling pathway and of synaptic plasticity-related proteins (NF200, GAP-43, Synapsin, and PSD95) analyzed by polymerase chain reaction and western blot assay. The mRNA expression is described by the optical density ratio relative to the control group. Protein expression was described by the optical density ratio relative to β-actin. Data are presented as mean ± SD. ***P < 0.001, vs. control group; ###P < 0.001 (one-way analysis of variance with post hoc Bonferroni test). All experiments were repeated three times. GAP43: growth associated protein 43; iPSC-NPCs: induced pluripotent stem cells-derived neural progenitor cells; NF200: neurofilament 200; OGD: oxygen-glucose deprivation; p-Akt: phosphor-Akt; PSD95: postsynaptic density protein 95; PTEN: phosphatase and tensin homolog deleted on chromosome ten.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.